Literature DB >> 11405088

Increased susceptibility to apoptosis in circulating lymphocytes of critically ill patients.

S Schroeder1, C Lindemann, D Decker, S Klaschik, R Hering, C Putensen, A Hoeft, A von Ruecker, F Stüber.   

Abstract

BACKGROUND AND AIMS: Lymphocyte apoptosis may influence immune responsiveness in systemic inflammation. Therefore, we investigated whether early signs of apoptosis (i.e., annexin-V binding and cell shrinkage) in peripheral lymphocytes were different among patients with severe sepsis, critically ill, nonseptic patients after major surgery, and healthy individuals. PATIENTS/
METHODS: Ten patients with severe sepsis and ten critically ill, nonseptic patients after major surgery admitted to a surgical intensive care unit in a university hospital were included in the study. In addition, ten healthy blood donors were included for comparison. We investigated early signs of apoptosis using flow cytometric measurement of annexin-V binding to the cell surface and cell shrinkage of peripheral lymphocytes.
RESULTS: The percentage of apoptotic lymphocytes determined as annexin-V positive and propidium iodide negative cells was increased in freshly prepared cells of patients with severe sepsis (11.4 +/- 0.5%) and critically ill, nonseptic patients after major surgery (18.5 +/- 2.0%) relative to healthy blood donors (4.4 +/- 0.5%) (P < 0.05). No significant difference between patients with severe sepsis and patients after major surgery were found. Annexin-V binding increased significantly after OKT-3 stimulation of lymphocytes in patients with severe sepsis (34.4 +/- 1.6%), patients after major surgery (33.8 +/- 3.4%), and healthy blood donors (21.1 +/- 2.8%). No significant difference among groups was detected following OKT-3 stimulation. Furthermore, freshly isolated peripheral lymphocytes of patients with severe sepsis and critically ill, nonseptic patients after major surgery revealed a significantly higher proportion of cell shrinkage than in healthy blood donors (55.0 +/- 2.2%, 21.5 +/- 2.4% vs 3.6 +/- 0.7%; P < 0.05).
CONCLUSION: Circulating lymphocytes of critically ill patients show a high degree of early signs of cellular apoptosis. This may contribute to hyporesponsiveness of immune cells in systemic inflammation.

Entities:  

Mesh:

Year:  2001        PMID: 11405088     DOI: 10.1007/s004230000181

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  6 in total

1.  Early trauma-hemorrhage-induced splenic and thymic apoptosis is gut-mediated and toll-like receptor 4-dependent.

Authors:  Gregory Tiesi; Diego Reino; Leonard Mason; David Palange; Jacquelyn N Tomaio; Edwin A Deitch
Journal:  Shock       Date:  2013-06       Impact factor: 3.454

2.  Relation between lymphopenia and bacteraemia in UK adults with medical emergencies.

Authors:  D H Wyllie; I C J W Bowler; T E A Peto
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

Review 3.  [Apoptosis as a pathomechanism in sepsis].

Authors:  S U Weber; J-C Schewe; C Putensen; F Stüber; S Schröder
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

Review 4.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

5.  VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis.

Authors:  Peter Weber; Ping Wang; Stephane Maddens; Paul Sh Wang; Rongqian Wu; Michael Miksa; Weifeng Dong; Michael Mortimore; Julian M C Golec; Peter Charlton
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

6.  Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis.

Authors:  Stefan U Weber; Jens-Christian Schewe; Lutz E Lehmann; Stefan Müller; Malte Book; Sven Klaschik; Andreas Hoeft; Frank Stüber
Journal:  Crit Care       Date:  2008-10-16       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.